Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,163
Recruiting: 2,261
Ph III recruiting: 270
Growth YoY: +12.5%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 601–650 of 1,971 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02705105	Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors	completed	Phase 1 / Phase 2	114	Kyowa Kirin, Inc.INDUSTRY	1	Apr 25, 2024	clinicaltrials
NCT04381910	Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer	completed	Phase 2	66	Luye Pharma Group Ltd.INDUSTRY	1	Apr 25, 2024	clinicaltrials